Product Description:

First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor that interrupts the pathways of VEGFR1,VEGFR2 and VEGFR3.It is used in the treatment of differentiated thyroid cancer (DTC),renal Cell Carcinoma and Hepatocellular Carcinoma (HCC)

Product Features:

Product Name : Lenvanix
Generic Name : Lenvatinib
Formulation : Capsule
Available Pack Size : 30’s Pot
Available Strength :  4 mg and 10 mg
Registrations Available
Website :